(TheNewswire)
Sernova Retains Integral WealthSecurities for Market Making Services
October 27, 2020 9:00 a.m. EDT
LONDON, ONTARIO - TheNewswire - October 27, 2020 - Sernova Corp.(TSXV:SVA) (OTC:SEOVF) (FSE:PSH) , aclinical-stage regenerative medicine company, announced today that Dr.Philip Toleikis, President and CEO, will provide an investorpresentation at the upcoming TSX Life Sciences Investor Day being heldon October 29, 2020, from 11:00 AM - 12:30 PM EST hosted by theToronto Stock Exchange and the TSX Venture Exchange.
For more details on the event or to register to hearpresentations from some of the most interesting public and privateLife Sciences companies from Canada, please click HERE .
Sernova also announces having retained the services ofIntegral Wealth Securities Limited to provide market-making servicesfor the Company in compliance with the applicable policies of the TSXVenture Exchange. Integral will trade the securities of Sernova on theTSX Venture Exchange for the purpose of maintaining an orderly marketand to provide liquidity of the Company's common shares.
Under the conditions of the agreement, Integral will bepaid $7,000 per month for their services for a minimum term of 12months. During the initial 12-month period, Sernova will have aone-time right to terminate after three months, provided writtennotice of termination is received at least 7 days prior to the 90thday of the term. After the 12th month of the term, this agreement maybe terminated by the Company upon 30 days written notice.
There are no performance factors contained in theagreement, and Integral will not receive shares or options ascompensation. Sernova and Integral are unrelated entities, andIntegral has no present direct or indirect interest in the Company orits securities.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicinetherapeutic solutions using a medical device (Cell Pouch(TM)) andimmune protected therapeutic cells/tissues (i.e. human donor cells,corrected human cells, and stem cell-derived cells) to improve thetreatment and quality of life of people with chronic metabolicdiseases such as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through cellular production ofproteins or hormones missing or in short supply within the body. Formore information, please visit www.sernova.com .
ABOUT SERNOVA'S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is anovel, proprietary, scalable, implantable macro-encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device, upon implantation, is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins, hormones, or other factors as required to treatdisease. Sernova is currently conducting a Phase I/II study at theUniversity of Chicago and has demonstrated encouraging early safetyand efficacy indicators. The Cell Pouch, in combination withtherapeutic cells/tissues, has been shown to provide long-term safetyand efficacy in preclinical models of diabetes, hemophilia A and otherindications supporting our therapeutics platform.
For further information contact:
Dominic Gray
Sernova Corp
Tel: (519) 858-5126
Forward-Looking Information
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute"forward-looking statements" that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of theCompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management's beliefs with respectto future events and are based on information currently available tomanagement on the date such statements were made. Many factors couldcause Sernova's actual results, performances or achievements to not beas anticipated, estimated or intended or to differ materially fromthose expressed or implied by the forward-looking statements containedin this news release. Such factors could include, but are not limitedto, the Company's ability to secure additional financing and licensingarrangements on reasonable terms, or at all; ability to conduct allrequired preclinical and clinical studies for the Company's Cell PouchSystem and/or related technologies, including the timing and resultsof those trials; ability to obtain all necessary regulatory approvals,or on a timely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the Company's quarterly and annual filings available onwww.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2020 TheNewswire - All rights reserved.